Private Beta · Now Accepting Applications

Your personal AI analyst,
always on call.

MyBrief24 reads the market for you — then tells you exactly what it means for your decisions. Not just what happened. What it means. For you, right now.

Request Early Access See What You'd Get →
CBInsights
Tells you what happened
Bloomberg
Doesn't know your context
Morning Brew
Generic, no depth
MyBrief24
Tells you what it means — for you
Why MyBrief24

Other tools give you data.
We give you judgment.

Capability CBInsights Bloomberg Terminal AI Search Tools MyBrief24
Real-time market data △ Delayed ✓ Yes ✗ No ✓ Yes
"What does this mean for me?" ✗ You figure it out ✗ You figure it out △ Generic answer ✓ Personalized AI judgment
Personalized to your role & context ✗ No ✗ No ✗ No ✓ Full personalization
Proactive daily intelligence brief △ Newsletter only ✗ No ✗ No ✓ AI-generated, tailored daily
Conversational research copilot ✗ No ✗ No △ No market data ✓ Deep research with full context
Company knowledge graph △ Basic ✗ No ✗ No ✓ Full ecosystem graph
Institutional memory ✗ No ✗ No ✗ No ✓ Team decisions & context preserved
Reasoning transparency ✗ Black box ✗ Black box △ Inconsistent ✓ Sources + reasoning chain shown
AI Capabilities

This is what you'd actually see.

Real examples of MyBrief24's AI output — personalized intelligence, not raw data.

MyBrief24 · Your Morning Brief · July 1, 2026 · Personalized for: VC Partner — Enterprise AI
3 signals require your attention today
FUNDING
Anthropic closes $3B Series E at $60B pre-money valuation — largest AI round of 2026
What this means for you
This validates frontier model lab valuations but also sets a ceiling dynamic for mid-tier players. For your portfolio company Ansa AI (enterprise orchestration layer), this is net positive — Anthropic's aggressive enterprise push will expand the API-as-infrastructure buying pattern, creating more budget for orchestration tooling rather than direct competition. Watch their enterprise hiring pace (+15 ML roles posted this week) as a proxy for how fast they're commoditizing the model layer.
→ Suggested action: Schedule check-in with Ansa AI on positioning re: Anthropic enterprise
EXEC MOVE
Scale AI's VP of Product (Sarah Chen) left to found a new company — stealth mode
What this means for you
Scale AI's VP of Product departure follows their Chief Revenue Officer exit 6 weeks ago. Pattern signal: two senior exec departures in rapid succession often precede a strategic pivot or valuation reset, not random attrition. Combined with Scale AI's 23% headcount reduction in Q1, this may indicate pressure on their core data labeling business as synthetic data scales. If you're tracking enterprise data infrastructure, this space may see consolidation in 12-18 months.
→ Suggested action: Add Scale AI to 90-day watchlist for further exec movement signals
PRODUCT
Microsoft Copilot announced native integration with SAP — 50,000 enterprise customers reached
What this means for you
Microsoft is systematically closing off the enterprise AI middleware layer. This directly compresses the addressable market for standalone AI workflow tools targeting SAP or similar ERP users. For your deal pipeline, any B2B AI company whose GTM relies on "plugging into" SAP workflows needs to articulate a clear differentiation strategy today — this integration likely ships to GA within 90 days.
→ Suggested action: Review two pipeline companies whose pitch decks reference SAP integration
MyBrief24 · Research Copilot
JL
I'm evaluating the medical AI space — B2B focus, comfortable with a 5–7 year return horizon. Where should I be looking right now?
MB
Based on current data across 89 medical AI companies in our knowledge graph, here's where I'd focus: The B2B medical AI space is bifurcating. I'll give you the honest picture:
  • Workflow automation (billing, prior auth, scheduling) — most crowded, margin compression starting, avoid unless you have a clear network effect angle.
  • Clinical decision support with FDA clearance — highest regulatory moat, best 5–7yr fit for your horizon. Currently underfunded relative to opportunity. 12 companies reached clearance milestones in 2026.
  • Revenue cycle + value-based care analytics — fastest-growing sub-segment, 3 companies raised $100M+ this year. Competition heating up.
For your horizon, I'd center on clinical decision support. Here are 3 companies worth a closer look:
DeepCyte Inc. — oncology dx, FDA 510k cleared Jan 2026 Navega Therapeutics — rare disease AI, $45M Series A, strong IP moat Alume Biosciences — promising but crowded dermatology space, proceed with caution
Want me to run a full diligence summary on any of these, or pull their hiring and patent signals?
JL
Run the full profile on DeepCyte.
MB
Pulling DeepCyte's full intelligence profile — SEC filings, patent activity, hiring signals, founder backgrounds, competitive positioning...
MyBrief24 · Signal Alert — Watchlist
HIGH PRIORITY SIGNAL · Watchlist Company
Foundry Robotics Inc. — Series A candidate
14 minutes ago
12 new engineering job postings in 7 days — including 4 ML Infrastructure roles ↑ +340% vs 30d avg
2 new USPTO patent applications filed this week (manipulation + perception) New
GitHub commit frequency up 67% over 30 days across 3 repos ↑ 67%
CEO posted "can't say much yet but big news coming" — 3.2k engagements Watch
What this means — AI Analysis
The combination of rapid hiring + new patent filings + surging commit activity is a strong pre-announcement pattern. Across 47 similar companies in our dataset, this cluster of signals preceded a major product launch or fundraise announcement within 30–60 days in 78% of cases.

If you're considering Foundry Robotics for your pipeline, now is the optimal outreach window — valuations typically move 30–50% on announcement. Their last known valuation was $28M (Seed, Nov 2025).
5 Core Modules

Everything you need to
stay ahead.

Module 01

Daily Intelligence Brief

Every morning, a personalized briefing generated specifically for you — based on your role, portfolio, watchlist, and past behavior. Not a newsletter. An AI analyst's daily report, written for your decisions.

"Waymo's expansion looks like IPO narrative positioning, not organic growth — here's why that matters for your autonomous vehicle bet..."
Module 02

Market Radar & Signal Alerts

Real-time anomaly detection across hiring, patents, GitHub, news, and social signals. MyBrief24 watches your watchlist 24/7 and alerts you the moment something meaningful shifts — with an explanation of what it likely means.

"Competitor hired 12 ML engineers + filed 2 patents this week. Pre-announcement pattern detected. Optimal outreach window: now."
Module 03

Research Copilot

A conversational AI research partner with full access to our knowledge graph. Ask complex, multi-part research questions in natural language. Get structured analysis, company recommendations, and one-click diligence summaries.

"Find me B2B medical AI companies with FDA clearance, less than $50M raised, founded after 2020, strong IP position."
Module 04

Company Intelligence Profiles

Every tracked company has a living, AI-generated intelligence profile — updated continuously. Funding history, product evolution, team changes, competitive positioning, signal dashboard. See any company at any point in time.

"Show me Ansa AI's state in January 2026 vs today — what changed, what signals emerged, what the AI thinks about trajectory."
Module 05 · Teams & Institutions

Institutional Memory

Your team's past decisions, discussions, and judgments — preserved, searchable, and connected to outcomes. New partners can instantly access the firm's accumulated intelligence. Track how your own views evolve over time. The longer you use MyBrief24, the smarter your collective judgment gets.

"You passed on DeepCyte in March 2025 — your note said 'reimbursement risk too high.' FDA cleared their device in January 2026. Here's what changed."
Who It's For

Built for decisions
that move markets.

VC / PE / Angel
The Investor

Evaluating 50 companies a month. Needs to know what signals matter, what competitors are doing, and when to move fast.

Startup C-Suite
The Founder & CEO

A competitor just raised $50M. A key player just exited. What does this mean for our fundraise timing, strategy, positioning?

Corp Dev / Strategy
The Strategist

Tracking M&A targets, mapping the competitive landscape, briefing the board. Needs deep research in hours, not weeks.

Research & Analysis
The Analyst

Writing sector reports on tight deadlines. Needs comprehensive, sourced intelligence across hundreds of companies — fast.

Early Access

Be the analyst
who always knows first.

We're opening MyBrief24 to a small group of investors, founders, and strategists. Apply below — we'll review personally.

We review every application personally. No spam, ever.

Application received.

We'll review your application and reach out personally. In the meantime — the market keeps moving, and so do we.